Pharmacogenomics in ophthalmology

Stephen G. Schwartz, Tomomi Higashide, Milam A. Brantley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pharmacogenomics is an evolving research discipline within ophthalmology, but genetic data are not currently used to guide daily clinical decisions. Ophthalmic pharmacogenomic research has thus far focused on open-angle glaucoma (OAG) and age-related macular degeneration (AMD), two common and worldwide causes of visual loss. In the treatment of OAG and allied disorders, there are reported associations between various polymorphisms in adrenergic receptor genes and topical β-antagonists as well as between the prostaglandin receptor gene and a topical prostaglandin analogue. In the treatment of exudative AMD, there are reported associations between AMD-associated genes, such as complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), and the efficacy of different treatment modalities including photodynamic therapy and intra- vitreal vascular endothelial growth factor (VEGF) antagonists. The steroid response associated with ophthalmic corticosteroids has been investigated, but no definite genetic associations have been reported. As additional pharmacogenomic trials are reported, the precise relationship between genotype and treatment response may become clearer.

Original languageEnglish (US)
Title of host publicationOmics for Personalized Medicine
PublisherSpringer India
Pages761-772
Number of pages12
ISBN (Electronic)9788132211846
ISBN (Print)9788132211839
DOIs
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Pharmacogenomics in ophthalmology'. Together they form a unique fingerprint.

  • Cite this

    Schwartz, S. G., Higashide, T., & Brantley, M. A. (2013). Pharmacogenomics in ophthalmology. In Omics for Personalized Medicine (pp. 761-772). Springer India. https://doi.org/10.1007/978-81-322-1184-6_32